Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

NCT02836496 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

108

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypereosinophilic Syndrome

Interventions

DRUG: Mepolizumab 300 mg
DRUG: Placebo matching mepolizumab
DRUG: Active OCS capsules (5 mg prednisolone or prednisone)
DRUG: Placebo matching OCS capsules

Sponsor

GlaxoSmithKline